ClinicalNews.Org

About ClinicalNews.Org

My Personal Biomedical Research Feed - Ralph Turchiano, CEO Alchepharma

Publisher

Ralph Turchiano

Category

health & fitness

Language

en

Explicit

No

First episode

10 Mar 2021

Latest episode

18 Oct 2026

Latest episodes

230 episodes in the feed.

1. 

   18 Oct 2026

   The Body's Hidden Drain: Methionine, Kidneys and Inflammation Ep. 1315 OCT 2026

   The Body's Hidden Drain: Methionine, Kidneys and Inflammation A methionine-rich diet helped mice survive a severe infection by helping their kidneys clear inflammation from the blood: about 7 in 10 were alive after one week, versus about 2 in 10 on normal food. In this Salk Institute study, extra methionine was converted into SAM (S-adenosylmethionine, the molecule sold as SAMe), which switched on the mTORC1 growth signal in the kidneys, so they grew, filtered about 2.5 times faster, and flushed inflammatory cytokines out through urinary excretion. The diet didn't kill more germs. Germ counts stayed the same; what changed was the cleanup. When the researchers added the inflammation signals back, the protection disappeared. In this episode: - How the experiment worked, step by step - Each link the team tested: methionine → SAM → mTORC1 → faster kidney filtering - Two more illness models, including a bloodstream infection - The reality check: a mouse study, the diet started two weeks before infection, not yet tested in people - The mouse dose in human terms, next to what Americans already eat (about 2 g a day) - Methionine-rich foods, and the studies that didn't make the cut 00:00 - Introduction: The Life-or-Death Amino Acid 01:20 - Survival Rates Across Diets 02:19 - Cytokines & The Kidney as a Filtration System 03:06 - The Problem with Cytokine Storms 03:49 - How the Kidneys Expand Under Stress 04:42 - Breaking Down the Groundbreaking Study 06:25 - Methionine's Impact on Sepsis & Kidney Injury 06:43 - Longevity vs. Acute Infection Context 08:05 - Human Dosage & Body Surface Area (BSA) 08:38 - Foods Highest in Methionine 09:54 - Clearance via Kidneys vs. Suppressing Inflammation 11:21 - Publication Bias & Study Limitations 12:24 - Future Medical Potential & Summary This is educational content, not medical advice. Please don't start methionine or SAMe supplements based on animal research; talk with your doctor first. 📄 Study: Troha K, et al. Dietary methionine mitigates immune-mediated damage by enhancing renal clearance of cytokines. Cell Metabolism 38, 298–315 (2026). doi:10.1016/j.cmet.2025.12.011 🤝 Created together: Ralph Turchiano (VHFILM) × Claude (Anthropic) #Methionine #Inflammation #KidneyHealth #Sepsis

2. 

   11 Oct 2026

   The Stiff-Heart Switch: Urolithin A and Heart Failure (HFpEF) Ep. 1314 OCT 26

   Why do millions of hearts pump normally yet still leave people breathless? In heart failure with preserved ejection fraction (HFpEF, said "heff-peff"), the heart squeezes fine but is too stiff to relax and refill. It affects an estimated 20 million-plus people worldwide and is hard to spot and hard to treat. A new study from King's College London found a hidden relaxation switch inside heart muscle, an enzyme called PKGIα with one tiny chemical handle (cysteine 42). Urolithin A, a molecule gut bacteria make from pomegranates, walnuts and berries, grabbed that handle and loosened stiff hearts in mice, improving filling, scarring and running distance. In mice bred without the handle, it did nothing. Lab-grown human heart tissue also relaxed faster. What it is not: a treatment. This was male mice for one week plus lab tissue, using purified urolithin A at doses above anything food provides. We translate the mouse dose into human terms and walk through what would still need to be proven in people. ⏱️ Video Chapters 00:00 - Introduction: Pomegranates & Heart Failure (HFpEF) 00:34 - What is HFpEF? The Stiff Heart Challenge 01:15 - Gut Microbes, Urolithin A & The Relaxation Switch 02:03 - Why This Matters: Prevalence & Symptoms 03:05 - Study Overview: Unpacking the Research & Challenges in Treatment 04:01 - The Science: PKG1α, Cysteine Activation & Heart Function Results 05:20 - Infographic Breakdown: Fibrosis, Heart Rate & Muscle Cell Size 05:50 - Real-World Translation: What This Could Mean for Everyday Life 07:14 - Safety Profile, Oral Dosing & Body Surface Area Conversion 08:48 - Comparison to Muscle Dosing & Supplement Safety Margins 09:27 - Study Protocol, Diet Models & Limitations 10:13 - Navigating Research Quality: Study Selection & Scientific Rigor 11:30 - Accessing Full Infographics & Concluding Thoughts 🔍 Key Highlights Covered: The Stiff Heart Problem: About 43% of heart failure cases involve preserved ejection fraction (HFpEF), where the heart pumps normally but struggles to relax and fill with blood. The Mechanism: Urolithin A targets a specific cysteine residue on PKG1α, triggering the pathway that allows cardiac muscle relaxation and reduced fibrosis. Translational Potential: Comparing animal dosing to human equivalents and what human clinical trials will need to confirm. 📌 Resources & References: Find full infographics and detailed study breakdown notes at clinicalnews.org. 📄 Study: Su J, Zhao Y, Coleman P, et al., Burgoyne JR. Targeting PKGIα Cys42 attenuates cardiac dysfunction in heart failure with preserved ejection fraction. Science Advances 12, eaec8088 (2026). https://doi.org/10.1126/sciadv.aec8088 ⚠️ Educational purposes only. Not medical advice. If you have heart failure, talk with your cardiologist before adding any supplement. Non-monetized, no sponsorships. Narrator: Ralph Turchiano | Analysis: Claude (Anthropic) ClinicalNews.org | VHFILM #UrolithinA #HeartFailure #HFpEF #HeartHealth #ScienceNews

3. 

   4 Oct 2026

   This Vitamin C Trial Found Something Nobody Expected Ep. 1313 OCT 2026

   A real, randomized, double-blind, placebo-controlled trial tested something almost nobody had properly studied: whether a cheap, safe vitamin could do anything for a precancerous blood condition. The trial's own main test failed. Everything downstream of that got genuinely strange. 109 adults with CCUS or a lower-risk myeloid malignancy — not on chemotherapy or radiation — were randomly assigned to 1000mg/day oral vitamin C (ascorbic acid) or a matching placebo, for 12 months, then tracked for years afterward. The primary endpoint — whether vitamin C slowed the growth of the cancer-linked mutant cell population — showed no difference. Null result, p=0.70. That's the headline nobody puts in a title, and it's the most important number in the whole study. But almost everything else measured told a different story: – Overall survival was dramatically better with vitamin C — though this was an unplanned, after-the-fact analysis, not something the trial was built or powered to test – Serious health complications were lower with vitamin C than placebo (33% vs. 57%) — unusual for an active treatment arm to look safer than sugar pills – Six inflammation-related markers shifted significantly, even though the intended molecular target never moved – Over half of participants were vitamin C deficient at baseline, with zero visible symptoms — and a single daily pill reliably corrected it while placebo did nothing And then there's the part that doesn't have a clean explanation yet: the vitamin C group started the trial with objectively worse disease — more co-occurring mutations, a worse molecular risk score — and still came out ahead. That rules out the easiest explanation (they were just the healthier group by chance) and leaves the real mechanism more open than before. We walk through all of it: what a hazard ratio actually means, why "post hoc" and "exploratory" results carry less weight than a trial's real primary endpoint, why nobody knows what patients did with vitamin C on their own after the study drug stopped, and why the honest conclusion here is "run a bigger trial" — not "start taking this." 📄 Study: Mikkelsen et al. "Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance." Cancer (2026). 🔗 Registered trial: ClinicalTrials.gov NCT03682029 Full sourcing and breakdown on ClinicalNews.org ⚠️ Educational content only. Not medical advice. This is early-phase, hypothesis-generating research — consult a hematologist before making any decisions about supplementation. #VitaminC #BloodCancer #ClinicalTrial #CCUS #Hematology #ClinicalResearch #ScienceCommunication

Who has been a guest on ClinicalNews.Org

Names identified in recent episode analyses. Showing up to five guests.

• Dr Ai
• [Guest Name Credential]
• Tsai Y-T
• Lin Y-C

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

YouTube views

1,151,850

Score snapshot 15 Sept 2025

Spotify

5.0 / 5

2 ratings

Podcast Authority Score: 73 / 100

A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.

Quality

81

Social presence

0

YouTube

93

Engagement

68

Contact ClinicalNews.Org

Guest appearances

Books guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.

Questions about ClinicalNews.Org